Technetium Behavior and Recovery in Soil

Technetium-99 in soils is of great concern because of its long half-life and because it can not be detected readily. This work reviews the behavior of technetium in various types of soils. A method for extracting technetium from soil was developed with the use of technetium-95m and 99m to determine recoveries at each step. Technetium chemistry is very complicated and problem areas in the behavior and recovery have been highlighted. Technetium is widely used in nuclear medicine and a review of its chemistry pertaining to radiopharmaceuticals is relevant and helpful in environmental studies. The technetium behavior in the patented citric acid method for the removal of toxic metals in contaminated soils was studied. An innovative method using solid phase extraction media for the concentration of technetium extracted from soils, with water and hydrogen peroxide, was developed. This technique may have a useful environmental application for this type of remediation of technetium from contaminated soils

Phosphordüngewirkung karbonisierter Biogasgärreste

P-recycling from biogas residue may play a future key role for sustainable P supply in organic farming. However, in particular transportation costs of residue need to be reduced e.g. by pretreatment. One approach is carbonization by pyrolysis or hydrothermal carbonization (HTC). In a pot trial with maize on a P-deficient, acidic sandy loam P uptake after application of two chars from pyrolysis (400 and 700 °C) and HTC (6 and 8 h dwell time) all made of the same residue was compared to P uptake after application of the raw residue and water soluble KH2PO4 respectively. P uptake was the same for KH2PO4, raw residue and both HTC treatments, but was significant lower in treatments with pyrolytic chars. Neither dwell time nor temperature had an effect. However, whereas pyrolysis raised P concentration, in HTC chars it was the same as in the raw residue. Also P was extracted from soil of pots without plants at beginning, half and end of the trial using H2O, CAT, CAL and Na-formate respectively. For CAT, CAL and Na-formate significant correlations between P uptake by maize and extractable P at all dates exist, whereas for H2O this was only true for extractable P at the end of the trial

Organische Dünger in Topfkulturen auf dem Prüfstand - wie steht es mit der Stickstofffreisetzung?

Matching nitrogen demand of plants and N release of organic fertilizers with respect to amount and timing is one key for successful cultivation of organic ornamentals. Thereby for plants with a low to moderate N demand growers can add the fertilizer as complete preplant application (CPA). For plants with a high N demand splitting fertilization in a reduced preplant application combined with an additional fertigation (RPA+F) is preferable. Aim of the current research was the investigation of N release of organic fertilizers in incubation experiments. Results of the incubation experiment were linked to a pot trial with pelargonium. Incubation experiments reveal that most fertilizers release about 40 to 50 % of total N and most nitrogen is released within the first 21 days. Only for sheep wool a delay of N release up to ten days was found. CPA using sheep wool and RPA+F (irrespective of fertilizer) give the best results. The delayed release pattern of sheep wool seems to match best N demand of plants

Development of a new radiolabel (lead-203) and new chelating agents for labeling monoclonal anntibodies for imaging

High liver uptake and slow body clearance presently limit the usefulness of /sup 111/In labeled antibodies for tumor imaging. We have investigated /sup 203/Pb as an alternate and better antibody label. The DTPA and cyclohexyl EDTA (CDTA) conjugates of an anticolon carcinoma antibody, 17-1A were labeled (bicyclic anhydride method) with /sup 203/Pb and /sup 111/In with 60 and 90% labeling yields, respectively. The biodistribution of /sup 203/Pb-17-1A conjugates was compared with the corresponding /sup 111/In-labeled preparations and with /sup 203/Pb-DTPA, /sup 203/Pb-nitrate and nonrelevant antibody controls in normal and human tumor (SW948) xenografted nude mice at 24, and 96 hr. Lead-203-labeled CDTA and DTPA antibody conjugates gave similar in vivo distributions. Even though the lead bound to these chelate-antibody conjugates was more labile in serum and in vivo, compared to indium, it cleared much faster from the liver and the whole body. A new series of chelating agents based on the incorporation of a trans-1,2- diaminocyclohexane moiety into the carbon backbone of polyaminocarboxylates is being synthesized. These are expected to provide stronger complexing ability for lead and produce greater in vivo stability. These ligands are also expected to be superior to EDTA and DTPA for labeling antibodies with other radiometals, including indium. 32 refs., 3 tabs

Development and evaluation of copper-67 and samarium-153 labeled conjugates for tumor radioimmunotherapy

The potential of utilizing receptor-specific agents such as monoclonal antibodies (MAb), and MAb-derived smaller molecules, as carriers of radionuclides for the selective destruction of tumors has stimulated much research activity. The success of such applications depends on many factors, especially the tumor binding properties of the antibody reagent, the efficiency of labeling and in-vivo stability of the radioconjugate and, on the careful choice of the radionuclide best suited to treat the tumor under consideration. The radiolabeled antibody technique for radioimmunotherapy (RIT), however, has experienced many limitations, and its success has not matched the expectations that were raised more than a decade ago. The problems that have been identified include: (i) degradation of antibody immunoreactivity resulting from chemical manipulations required for labeling; (ii) lack of suitable radioisotopes and methods for stable attachment of the radiolabel; (iii) in-vivo instability of the radioimmunoconjugates; (iv) excessive accumulation of activity in non-target locations; and (v) lack of radioimmunoconjugate accessibility to cells internal to a tumor mass. A careful choice of the radionuclide(s) best suited to treat the tumor under consideration is one of the most important requirements for successful radioimmunotherapy. This study evaluates copper 67 and samarium 153 for tumor radioimmunotherapy

Comparative Expression Profiling of the Chlamydia trachomatis pmp Gene Family for Clinical and Reference Strains

Chlamydia trachomatis, an obligate intracellular pathogen, is a leading worldwide cause of ocular and urogenital diseases. Advances have been made in our understanding of the nine-member polymorphic membrane protein (Pmp) gene (pmp) family of C. trachomatis. However, there is only limited information on their biologic role, especially for biological variants (biovar) and clinical strains.We evaluated expression for pmps throughout development for reference strains E/Bour and L2/434, representing different biovars, and for clinical E and L2 strains. Immunoreactivity of patient sera to recombinant (r)Pmps was also determined. All pmps were expressed at two hours. pmpA had the lowest expression but was up-regulated at 12 h for all strains, indicating involvement in reticulate body development. For pmpD, expression peaked at 36 h. Additionally, 57.7% of sera from infected and 0% from uninfected adolescents were reactive to rPmpD (p = 0.001), suggesting a role in immunogenicity. pmpF had the highest expression levels for all clinical strains and L2/434 with differential expression of the pmpFE operon for the same strains. Sera were nonreactive to rPmpF despite immunoreactivity to rMOMP and rPmpD, suggesting that PmpF is not associated with humoral immune responses. pmpFE sequences for clinical strains were identical to those of the respective reference strains. We identified the putative pmpFE promoter, which was, surprisingly, 100% conserved for all strains. Analyses of ribosomal binding sites, RNase E, and hairpin structures suggested complex regulatory mechanism(s) for this >6 Kb operon.The dissimilar expression of the same pmp for different C. trachomatis strains may explain different strain-specific needs and phenotypic distinctions. This is further supported by the differential immunoreactivity to rPmpD and rPmpF of sera from patients infected with different strains. Furthermore, clinical E strains did not correlate with the E reference strain at the gene expression level, reinforcing the need for expansive studies of clinical strains

Adeninnucleotide und freie Aminosäuren in der Rattenleber sowie Aminosäure- und Corticosteronspiegel im Serum von Ratten nach Verbrennungen

Peer Reviewe

Correlating labeling chemistry and in-vitro test results with the biological behavior of radiolabeled proteins

Monoclonal antibodies possess enormous potential for delivery of therapeutic amounts of radionuclides to target antigens in vivo, in particular for tumor imaging and therapy. Translation of this concept into practice has encountered numerous problems. Specifically whereas general protein radiolabeling methods are applicable to antibodies, immunological properties of the antibodies are often compromised resulting in reduced in-vivo specificity for the target antigens. The bifunctional chelating agent approach shows the most promise, however, development of other agents will be necessary for widespread usefulness of this technique. The effects of labeling chemistry on the in-vivo behavior of several monoclonal antibodies are described. 30 refs., 4 figs., 10 tabs

Eignung von Substraten aus Baumrinde im Gartenbau unter besonderer Beruecksichtigung der Verfuegbarkeit von Pflanzennaehrstoffen und deren Bestimmung Abschliessender Sachbericht

SIGLETIB: D.Dt.F./AC 1000 (18,18) / FIZ - Fachinformationszzentrum Karlsruhe / TIB - Technische InformationsbibliothekDEGerman

Recent developments in blood cell labeling research

A number of recent developments in research on blood cell labeling techniques are presented. The discussion relates to three specific areas: (1) a new in vitro method for red blood cell labeling with /sup 99m/Tc; (2) a method for labeling leukocytes and platelets with /sup 99m/Tc; and (3) the use of monoclonal antibody technique for platelet labeling. The advantages and the pitfalls of these techniques are examined in the light of available mechanistic information. Problems that remain to be resolved are reviewed. An assessment is made of the progress as well as prospects in blood cell labeling methodology including that using the monoclonal antibody approach. 37 refs., 4 figs